Person: BOZKURT, SÜHEYLA
Loading...
Email Address
Birth Date
Research Projects
Organizational Units
Job Title
Last Name
BOZKURT
First Name
SÜHEYLA
Name
17 results
Search Results
Now showing 1 - 10 of 17
Publication Open Access Mesenchymal stem cells differentiate to retinal ganglion-like cells in rat glaucoma model induced by polystyrene microspheres(2023-10-01) ERASLAN, MUHSİN; ÇERMAN, EREN; BOZKURT, SÜHEYLA; AKKOÇ, TUNÇ; ERASLAN M., ÇERMAN E., BOZKURT S., Genç D., Virlan A. T., Demir C. S., Akkoç T., Karaöz E., AKKOÇ T.Aim: The study aimed to evaluate the differentiation ability of intravitreally injected rat bone marrow-derived mesenchymal stem cells (rBM-MSCs) to retinal ganglion-like cells in a polystyrene microsphere induced rat glaucoma model. Materials and Methods: The glaucoma rat model was generated via intracameral injection of 7 microliter polystyrene microspheres. Green fluorescence protein-labeled (GFP) rBM-MSCs were transplanted intravitreally at or after induction of ocular hypertension (OHT), depending on the groups. By the end of the fourth week, flat-mount retinal dissection was performed, and labeled against Brn3a, CD90, GFAP, CD11b, Vimentin, and localization of GFP positive rBM-MSCs was used for evaluation through immunofluorescence staining and to count differentiated retinal cells by flow cytometry. From 34 male Wistar albino rats, 56 eyes were investigated. Results: Flow cytometry revealed significantly increased CD90 and Brn3a positive cells in glaucoma induced and with rBM-MSC injected groups compared to control(P = 0.006 and P = 0.003 respectively), sham-operated (P = 0.007 and P < 0.001 respectively), and only rBM-MSCs injected groups (P = 0.002 and P = 0.009 respectively). Immunofluorescence microscopy revealed differentiation of GFP labeled stem cells to various retinal cells, including ganglion-like cells. rBM-MSCs were observable in ganglion cells, inner and outer nuclear retinal layers in rBM-MSCs injected eyes. Conclusion: Intravitreally transplanted rBM-MSCs differentiated into retinal cells, including ganglion-like cells, which successfully created a glaucoma model damaged with polystyrene microspheres. Promisingly, MSCs may have a role in neuro-protection and neuro-regeneration treatment of glaucoma in the future.Publication Open Access Langerhans cell histiocytosis located in the spheno-orbital bone and the pons: Illustrative case(2023-07-01) ÇEKİÇ, EFECAN; KARAGÖZ, AHMET; SAKAR, MUSTAFA; KAÇAR, KADRİYE EBRU; BOZKURT, SÜHEYLA; DAĞÇINAR, ADNAN; ÇEKİÇ E., Karagoz A., SAKAR M., Senay R. E., AKAR K. E., BOZKURT S., DAĞÇINAR A.BACKGROUND This is a case of aggressive Langerhans cell histiocytosis (LCH) with an atypical intracranial location. OBSERVATIONS In this report, the authors present the diagnosis and treatment of a 12-year-old male patient diagnosed with LCH. The patient was admitted to the emergency department with left-sided facial palsy, and a solid lesion with mass effect in the pons was found. A biopsy was performed via suboccipital craniotomy, and the diagnosis was LCH. A chemotherapy regimen was started since the LCH sample was the resistant type. The patient showed improvement in his neurological deficit following treatment. LESSONS This rare localized and aggressive case’s diagnosis process and treatment choices may apply to future cases. https://thejns.org/doi/abs/10.3171/CASE22367.Publication Metadata only Gastrointestinal kanal patolojisinde tuzaklar(Kongre Kitabevi, 2022-01-01) ÇELİKEL, ÇİĞDEM; BOZKURT, SÜHEYLA; ÇELİKEL Ç., GÜLLÜOĞLU M., BOZKURT S., DOĞANAVŞARGİL YAKUT B., SAKA B., GÖKSEL S., YAMAN B.Publication Metadata only Challenges in the management of a 7 years old child with thyrotropin-secreting pituitary adenoma and the review of the literature(2023-01-01) KIRKGÖZ, TARIK; GÜRPINAR TOSUN, BUŞRA; ELTAN, MEHMET; HALİLOĞLU, BELMA; KAYGUSUZ, SARE BETÜL; SEVEN MENEVŞE, TUBA; BOZKURT, SÜHEYLA; ÖNEŞ, TUNÇ; GÜRAN, TÜLAY; DAĞÇINAR, ADNAN; BEREKET, ABDULLAH; DEMİRCİOĞLU, SERAP; KIRKGÖZ T., Abali S., Seker A., GÜRPINAR TOSUN B., ELTAN M., Helvacioglu D., HALİLOĞLU B., KAYGUSUZ S. B., Yavas Abali Z., SEVEN MENEVŞE T., et al.Introduction: Thyrotropin-producing pituitary adenoma (TSHoma) is a very rare disease, representing less than 1% of the pituitary tumours, present with elevated thyroid hormones and normal/high TSH concentrations. Case Presentation: A 7-year-old boy with nervousness was referred by his psychiatrist for elevated free T4, T3 and TSH levels. Initial evaluation revealed an elevated -subunit.Pituitary MRI demonstrated a macroadenoma. The patient underwent a trans-sphenoidal tumour resection (TSS) which showed positive immunohistochemical staining for TSH, growth hormone, and prolactin in tumoral tissue. Euthyroidism was achieved for one year after TSS, then, recurrence of tumour with elevated TSH and thyroid hormone levels necessitated a re-operation with TSS followed by gamma-knife radiosurgery. The euthyroid state was achieved and lasted for 2.5 years this time, but, due to the recurrence, medical treatment had been commenced with cabergoline and octreotide. Euthyroidism was maintained for the last 4 years on monthly octreotide treatment. A repeat MRI demonstrated no pituitary mass but a mass in the sphenoidal sinus had been detected. Removal of this mass by surgery did not achieve euthyroidism. 68Ga-DOTA-TATE PET/CT showed residual tissue extending from the pituitary region to the sphenoid sinus.The patient\"s bone age was advanced 2 years at diagnosis which became 4 years in one year after the diagnosis and remained so throughout follow-up, leading to a final height of -3.3 SDS below his target height at the age of 16 years. Conclusion: The diagnosis, treatment, and follow-up of TSHomas are challenging and short stature due to accelerated bone maturation is a complication of paediatric TSHomas.Publication Open Access An Astonishing Extrarenal Wilms Localisation; Spinal Cord(2022-06-01) TOKUÇ, AYŞE GÜLNUR; BOZKURT, SÜHEYLA; KAÇAR, KADRİYE EBRU; EKER, NURŞAH; SAKAR, MUSTAFA; TOKUÇ A. G., EKER N., Tas B. T., BOZKURT S., SAKAR M., Aras S., AKAR K. E.Wilms\" tumour is a renal tumour mostly seen during the first 5 years of life and it accounts for 95% of renal malignancies during childhood. Its origin is primitive metanephric cells and, very rarely, it may occur in places other than the kidneys. The estimated rate of nephroblastoma outside the kidneys is approximately 0.5 to 1% of Wilms\" tumour cases. In this article, we report on a 3-year-old female patient who first presented with spinal dysraphism and a mass in the lumbar spinal cord with a histopathological diagnosis of nephrogenic rest, and after one year, a Wilms tumour arose in this location. This is a very rare extrarenal Wilms\" tumour location. Here, we report on a case with immature renal cells located in the lumber spinal cord associated with spinal dysraphism and the development of Wilms\" tumour there after one year.Publication Open Access Greater presence of receptors for relaxin in the ligamentum teres of female infants who undergo open reduction for developmental dysplasia of the hip(BMC, 2021-12) BOZKURT, SÜHEYLA; Ayanoglu, Semih; Cabuk, Haluk; Cabuk, Fatmagul Kusku; Beng, Kubilay; Yildirim, Timur; Bozkurt, Suheyla UyarBackground: While many factors involved in the etiology of developmental dysplasia of the hip (DDH), one of which is the hormone relaxin. Relaxin concentrations in patients with DDH may lead to pathodynamic changes during hip development by altering the physiological nature of the ligament, as well as by long-term exposure to relaxin during pregnancy. Our objective in this study was to determine the number of relaxin receptors in the ligamentum teres and their role in causing DDH. Methods: We identified 26 infants between birth and 3 years of age who had undergone open reduction for DDH between 2010 and 2012. 12 hips of 12 miss abortus fetus between 20 to 35 weeks of gestation were used as control group. Specimens obtained from two groups were stained with Relaxin-2 antibody, and the amount of staining for relaxin receptors was determined using an ordinal H score. Results: The mean (SD) H scores of infants with DDH were significantly higher than those of controls: 215 (59) versus 52 (48); P = 0.00; 95% CI. Statistically significant difference between the two groups in terms of gender was not found. Conclusion: As a result, increased number of relaxin receptors in the ligamentum teres could be a risk factor for DDH.Publication Open Access Pilocytic Astrocytoma of the Cerebellopontine Angle with cerebrospinal fluid Spread in an Adult: A Case Report(2022-12-01) KURŞUN, MELTEM; OĞUZSOY, TUBA; BOZKURT, SÜHEYLA; BAYRAKLI, FATİH; BIYIKLI, ERHAN; Bıyıklı E., Kurşun M., Oğuzsoy T., Bozkurt S., Bayraklı F.Introduction Pilocytic astrocytoma of the cerebellopontine angle (CPA) is uncommon, and its spread to the cerebrospinal fluid (CSF) at the time of diagnosis has not been reported in the literature. Case Presentation We report the case of a 33-year-old man with multifocal pilocytic astrocytoma diagnosed by magnetic resonance imaging (MRI) and confirmed by histopathological examination, and present the radiological and histopathological findings. Conclusion In the case herein reported, we observed spread of the pilocytic astrocytoma of the CPA to the CSF at the initial diagnosis, and early detection by MRI is very important regarding the treatment modality and prognosis.Publication Metadata only Past, present, and future of therapies for pituitary neuroendocrine tumors: need for omics and drug repositioning guidance(2022-03-01) ERDOĞAN, ONUR; ARĞA, KAZIM YALÇIN; BOZKURT, SÜHEYLA; BAYRAKLI, FATİH; YILMAZ, BETÜL; TURANLI, BESTE; Aydin B., Yildirim E., ERDOĞAN O., ARĞA K. Y., Yilmaz B., BOZKURT S., BAYRAKLI F., TURANLI B.Innovation roadmaps are important, because they encourage the actors in an innovation ecosystem to creatively imagine multiple possible science future(s), while anticipating the prospects and challenges on the innovation trajectory. In this overarching context, this expert review highlights the present unmet need for therapeutic innovations for pituitary neuroendocrine tumors (PitNETs), also known as pituitary adenomas. Although there are many drugs used in practice to treat PitNETs, many of these drugs can have negative side effects and show highly variable outcomes in terms of overall recovery. Building innovation roadmaps for PitNETs\" treatments can allow incorporation of systems biology approaches to bring about insights at multiple levels of cell biology, from genes to proteins to metabolites. Using the systems biology techniques, it will then be possible to offer potential therapeutic strategies for the convergence of preventive approaches and patient-centered disease treatment. Here, we first provide a comprehensive overview of the molecular subtypes of PitNETs and therapeutics for these tumors from the past to the present. We then discuss examples of clinical trials and drug repositioning studies and how multi-omics studies can help in discovery and rational development of new therapeutics for PitNETs. Finally, this expert review offers new public health and personalized medicine approaches on cases that are refractory to conventional treatment or recur despite currently used surgical and/or drug therapy.Publication Metadata only Decoding molecular signatures of pituitary neuroendocrine tumors’ subtypes through systems biomedicine perspective(2021-12-21) BAYRAKLI, FATİH; BOZKURT, SÜHEYLA; ARĞA, KAZIM YALÇIN; TURANLI, BESTE; AYDIN B., Yildirim Sirkeci E., ERDOĞAN O., BAYRAKLI F., BOZKURT S., ARĞA K. Y., TURANLI B.Publication Metadata only Prognostic factors in progressive high-grade glial tumors treated with systemic approach: A single center experience(SAGE PUBLICATIONS LTD, 2021) ATASOY, BESTE MELEK; Alan, Ozkan; Telli, Tugba Akin; Tuylu, Tugba Basoglu; Arikan, Rukiye; Demircan, Nazim Can; Ercelep, Ozlem; Kaya, Serap; Babacan, Nalan Akgul; Atasoy, Beste M.; Bozkurt, Suheyla; Bayri, Yasar; Gul, Dilek; Ekinci, Gazanfer; Ziyal, Ibrahim; Dane, Faysal; Yumuk, P. FuldenPurpose Malignant high-grade gliomas are the most common and aggressive type of primary brain tumor, and the prognosis is generally extremely poor. In this retrospective study, we analyzed the outcome of systemic treatment in recurrent high-grade glioma patients and the impact of prognostic factors on survivals. Methods Data from 114 patients with recurrent high-grade glioma who received systemic treatment and followed in our clinic between 2012 and 2018 were retrospectively analyzed. Eastern Cooperative Oncology Group (ECOG) performance status, age, gender, histology, type of surgical resection, side effects after systemic treatment (deep vein thrombosis, hypertension, proteinuria), IDH1 and alpha thalassemia/mental retardation syndrome X-linked (ATRX) mutation status were investigated as prognostic factors for progression-free survival and overall survival. Results At the time of diagnosis, the median age was 48 (17-77) and 68% of the patients were male. Most common pathologic subtype was glioblastoma multiforme (68%). Median follow-up duration was 9.1 months (1-68 months). Median progression-free survival and overall survival were 6.2 months and 8 months, respectively. In multivariate analysis, ECOG PS, deep venous thrombosis and the presence of ATRX and IDH1 mutation were found to be independent prognostic factors for progression-free survival (p < 0.05) and, ECOG PS, the presence of ATRX and IDH1 mutation for overall survival (p < 0.05). Conclusion Our study is real life data and the median progression-free survival and overall survival rates are similar to the literature. We have found ECOG PS, presence of ATRX and IDH1 mutation to be independent prognostic factors for both progression-free survival and overall survival.